Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave Ignite Study at the Annual Meeting of the American Diabetes Association
June 05, 2015 at 08:32 AM EDT
Orexigen Therapeutics (NASDAQ: OREX) announced today that two Contrave® (naltrexone HCI and bupropion HCI) abstracts will be presented ...